MISC

2018年12月

[A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].

Gan to kagaku ryoho. Cancer & chemotherapy
  • Mitsuyoshi Okazaki
  • Hidehiro Tajima
  • Yoshinao Ohbatake
  • Shiro Terai
  • Shinichi Nakanuma
  • Koichi Okamoto
  • Seisho Sakai
  • Isamu Makino
  • Jun Kinoshita
  • Keishi Nakamura
  • Tomoharu Miyashita
  • Hiroyuki Takamura
  • Itasu Ninomiya
  • Sachio Fushida
  • Tetsuo Ohta
  • 全て表示

45
13
開始ページ
2162
終了ページ
2164
記述言語
日本語
掲載種別
Scientific Journal

A 59-year-old man was admitted to our hospital for further investigation of abnormal uptake in the pancreatic body on positron emission tomography-computed tomography(PET-CT). He had chronic renal failure due to diabetic nephropathy, and had been on maintenance hemodialysis since he was 45-years-old. He was diagnosed with pancreatic body cancer(cT1c, cN0, cM0, cStageⅠa)and was treated preoperatively with neoadjuvant chemotherapy(gemcitabine plus nab-paclitaxel). After 2 courses, we performed distal pancreatectomy. Histopathological examination revealed no viable tumor cells(pathological complete response). The postoperative course was uneventful, and he is alive without recurrence at 6 months after surgery, without adjuvant chemotherapy. Our findings suggest that gemcitabine plus nab-paclitaxel is a useful treatment for patients with pancreatic cancer on hemodialysis.

リンク情報
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30692318
ID情報
  • ISSN : 0385-0684
  • PubMed ID : 30692318

エクスポート
BibTeX RIS